Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Maternity
  4. Back
  5. Infections (Maternity)
  6. Group B Streptococcal Prophylaxis (570)
Announcements and latest updates

Right Decision Service newsletter: October 2024

Welcome to the Right Decision Service (RDS) newsletter for October 2024.

1.Contingency arrangements for RDS outages

Development of the contingency solutions to maximise RDS resilience and minimise risk of future outages is in progress, aiming for completion by Christmas. As a reminder, these contingency arrangements  are:

  • Optimising mobile app build process
  • Mobile app always to be downloadable.
  • Serialising builds to mobile app; separate mobile app build from other editorial and end-user processes
  • Load balancing – provides failover (also enables separation of editorial processes from other processes to improve performance.)

 

In the meantime, a gentle reminder to encourage users to download essential clinical toolkits to their mobile devices so that there is an offline version always available.

 

2. New deployment with improvements.

A new scheduled deployment with minor improvements drawn from support tickets, externally funded projects, information related to outages, and feature requests will take place in early December. Key improvements planned are:

  • Deep-linking to individual toolkits within the RDS mobile app. Each toolkit will now have its own direct URL and QR code, both accessible from the app. These can be used to download the toolkit directly where users already have the RDS app installed. If the user does not yet have the RDS app installed, they will be taken to the app store to install the app and immediately afterwards the toolkit will automatically open and download. Note that this will go live a few days later than the improvements below due to the need to link up the mobile front end to the changes in the content management system.
  • Introducing an Announcement Header field to replace the hardcoded "Announcements and latest updates" text. This will enable users to see at a glance the focus of new announcements.
  • Automated daily emptying of the recycling bin (with a 30 day rolling grace period)  in the content management system. A bug preventing complete emptying of the recycling bin contributed to one of the outages earlier this year.
  • Supporting multiple passcodes (ticket 6079)
  • Expanding accordion section to show location of a search result rather than requiring user coming from a search result to manually open all sections and search again for the term.
  • Displaying first accordion section Content text as a snippet on the search results page as a fallback if default/main content is not provided
  • Displaying the context of each search result in the form of a link to the relevant parent tool/section. This will help users to choose which search result is most likely to be appropriate for their needs.
  • As part of release of the new national benzodiazepine quality prescribing guidance toolkit sponsored by Scottish Government Effective Prescribing and Therapeutics, a digital tool to support creation of benzodiazepine tapering/withdrawal schedules.

We are also seeking approval to use the NHS Scotland logo and title for the RDS app on the app stores to help with audience engagement and clarity around the provenance of RDS.

3. RDS Search, Browse and Archive/Version control enhancements

We are still hopeful that user acceptance testing for at least the Search and browse enhancements can take place before Christmas. Thank you for your patience and understanding in waiting for these improvements. Timescales have been pushed back by old app migration challenges, work to address outages, and most recently implementing the contingency arrangements.

4. Support tickets

We are aware that there continue to be some issues around a number of RDS support tickets, in part due to constraints around visibility for the RDS team of the tickets in the existing  support portal. We are investigating the potential to move to a new support ticket requesting system from early in the new year. We will organise the proposed webinar around support ticket processes once we have confirmed the way forward with the system.

Table formatting

There is a known issue with alterations in formatting of some RDS tables which seems to have arisen as a result of the 17 October deployment. Tactuum is working on a fix and on implementing additional regression testing to prevent this issue recurring.

5. New RDS toolkits

Recently launched toolkits include:

NHS Lothian Infectious Diseases

Scottish Health Technologies Group – Technology Assessment recommendations

NHS Tayside Anaesthetics and Critical Care projects – an innovative toolkit which uses PowerAutomate to manage review and response to proposals for improvement projects.

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

A number of toolkits are expected to go live before Christmas, including:

  • Focus on dementia
  • Highland Council Getting it Right for Every Child
  • Dumfries and Galloway Adult Support and Protection procedures
  • National Waiting Well toolkit
  • Fertility Scotland National Network
  • NHS Lothian postural care for care homes

6.Sign up to RDS Editors Teams channel

We have had a good response to the recent invitation to sign up to the new Teams channel for RDS editors. This provides a forum for editors to share learning, ideas and questions and we hope to hold regular webinars on topics of interest.  The RDS team is in the process of joining participants to the channel and we’d encourage all editors to take part, using the registration form – available in Providers section of the RDS Learning and Support area.

 

7. Evaluation projects

The RDS team has worked with colleagues in NHS Grampian and the Digital Health & Care Innovation Centre to evaluate the impact of the Prevent the progress of diabetes web and mobile app in a small-scale pilot project. This app provides access to local and national resources and services targeted at people with prediabetes, a history of gestational diabetes, or candidates for remission. After just 8 weeks of using the app, 94% of patients reported increased their knowledge and understanding of diabetes, and 88% said it had increased their confidence and motivation to make lifestyle changes, highlighting specific behaviour changes. The learning from this project is informing development of a service model based on tailored support for patient groups with, high, medium and low digital self-efficacy.

Please contact ann.wales3@nhs.scot if you would like to know more about this project.

  1. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 29th November 3-4 pm
  • Thursday 5 December 3.30 -4.30 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

The Right Decision Service:  the national decision support platform for Scotland’s health and care

Website: https://rightdecisions.scot.nhs.uk    Mobile app download:  Apple  Android

 

 

Group B Streptococcal Prophylaxis (570)

Warning

Audience

This guideline is applicable to all medical, nursing in midwifery staff caring for women and neonates in Greater Glasgow & Clyde. Staff should also be familiar with the relevant drug monographs.

Please report any inaccuracies or issues with this guideline using our online form

Introduction

Group B streptococcus is the commonest cause of early onset infection in the neonatal period. The organism frequently colonises the lower vagina or anorectum and may pass to the baby following rupture of the membranes, or occasionally prior to membrane rupture in the presence of amnionitis. This guideline aims to interrupt the transmission of GBS by giving intrapartum antibiotic prophylaxis to the mother. Two approaches have been used to identify mothers who should be offered intrapartum antibiotic prophylaxis. Mothers may be identified through routine bacteriological screening during the pregnancy or based on clinical risk factors for transmission of the organism. In the UK the Royal College of Obstetricians recommends the latter approach.

In 2012, NICE published guidance on antibiotics for the prevention and treatment of early onset neonatal infection (NICE CG149). This includes advice on maternal risk factors which warrant the use of intrapartum antibiotic prophylaxis. It also includes advice on the management of babies born to mothers with intrapartum risk factors, or where there are abnormal signs or symptoms in the baby, indicating an increased risk of early onset infection (including with Group B Streptococcus). All such babies are monitored using a Neonatal Early Warning Screening (NEWS) chart and some will receive antibiotics if there are multiple risk factors, signs or symptoms, or any single “red flag” risk factor, sign or symptom. This is all detailed in the neonatal Early Onset Sepsis (EOS) guideline.

Antenatal care

All pregnant women should be provided with an appropriate information leaflet regarding GBS.

Universal bacteriological screening is not recommended. A maternal request for screening is not an indication, but should be discussed with healthcare professionals on an individual basis.

Antenatal treatment is not recommended for GBS cultured from a vaginal or rectal swab. Women with GBS urinary tract infection (> 10cfu/ml) during pregnancy should receive appropriate treatment at the time of diagnosis, as well as intrapartum antibiotic prophylaxis.

Intrapartum antibiotic prophylaxis (IAP)

1– Prophylaxis cases

The following groups of women should be offered IAP with an intravenous antibiotic which is effective against GBS. This will be benzylpenicillin or, for penicillin sensitive women, teicoplanin.

  • Women in whom colonisation with GBS has been identified in current or previous pregnancy
  • Women with GBS bacteriuria in current or previous pregnancy
  • Women with previous baby affected by early- or late-onset neonatal GBS disease
  • Women in confirmed preterm labour< 37+0 weeks gestation

Women with GBS detected in a previous pregnancy have a 50% risk of recurrent GBS carriage and should be offered routine IAP or the option of bacteriological testing in late pregnancy, followed by IAP if still positive.

If performed, bacteriological testing should be carried out at 35-37 weeks gestation or 3-5 weeks prior to the anticipated delivery date, i.e. 32-34 weeks gestation in multiple pregnancies. A single (Amies charcoal) swab should be taken from the lower vagina and anorectum. Healthcare professionals should indicate that the swab is being taken for GBS.

2– Potentially infected women who require antibiotics that also cover GBS

In women:

  • Where chorioamnionitis is suspected
  • Who have a pyrexia during labour (> 38°C) or a temperature of ≥ 37.5°C on 2 separate occasions at least 2 hours apart or maternal sepsis with a temperature < 36°C
  • For whom the sepsis 6 bundle is triggered

Antibiotic therapy should be according to GGC guidelines but in addition, must include specific GBSprophylaxis as below.

Intrapartum prophylaxis

(to start at the onset of labour)

Benzylpenicillin 3 g IV loading infusion over 30 minutes followed every 4 hours by 1.8 g IV infusion over 30 minutes until delivery. For women who have a genuine allergy to penicillin, give Teicoplanin 12 mg/kg * over 3-5 minutes as a slow IV bolus or over 30 minutes by IV infusion every 12 hours until delivery. (See Appendix 1)

* based on most recent body weight – round each dose to nearest 100 mg (max 800 mg)

Antibiotic therapy for women with suspected chorioamnionitis, intrapartum pyrexia or sepsis should be reviewed at delivery and/or after a maximum of 48 hours.

Clinicians should be aware of the potential adverse effects of IAP including anaphylaxis.

Effective prophylaxis

Prophylaxis is more effective if the first dose is given at least 4 hours prior to delivery and continued at the correct intervals. Antibiotics should be started as soon as possible after the onset of labour and continued until delivery. Prophylaxis is considered to have lapsed if a dose is more than 1 hour late. If prophylaxis with benzylpenicillin has lapsed a 3g loading dose is required rather than the routine 1.8g dose.

NB – As the primary goal of IAP is to prevent transmission of GBS to the neonate, it is vital to give effective prophylaxis even if the baby will receive antibiotics after delivery due to the presence of other risk factors for early onset sepsis.

Women who are receiving prophylactic antibiotics for GBS in labour who require a caesarean section will still require routine co-amoxiclav or clindamycin cover  (See antibiotic guideline).

Irrespective of gestation and the presence of risk factors for GBS transmission, IAP is not required if delivery is by planned caesarean section with intact membranes and the baby is clinically well.

 

Management of rupture of membranes to reduce the risk of GBS transmission

Women with rupture of membranes at term (≥ 37+0 weeks gestation) who are known GBS carriers should be offered immediate IAP and induction of labour as soon as reasonably possible.

Bacteriological testing for GBS carriage is not recommended for women with preterm prelabour rupture of membranes. IAP should be given once labour is confirmed or induced irrespective of GBS status. However, known GBS colonisation should be taken into consideration when making decisions about timing of delivery in women with preterm prelabour rupture of membranes. For those at more than 34+0 weeks of gestation it may be beneficial to expedite delivery if the woman is a known GBS carrier.

Communication

It  will  be  the  responsibility  of  the  labour ward  staff  to  communicate  to  the neonatologist  the following information:

  • That risk factors for early onset neonatal GBS disease have been identified
  • Whether prophylaxis has been started and, if so, how long prior to delivery
  • Whether there is evidence of maternal sepsis

The requirement for prophylaxis should be recorded on the alert area in the maternal notes.
Remember if mother is septic ensure neonatologist informed.

Frequently asked questions (FAQ)

Parents who decline intrapartum antibiotic prophylaxis or empirical treatment for their baby

We recommend GBS prophylaxis. Intrapartum prophylaxis may be declined despite this advice. Empirical therapy for well infants born to mothers with risk factors may also be declined.

If parents decline these interventions the medical staff should ensure that they are aware of the level of risk of early onset GBS disease and the life threatening nature of GBS sepsis. The infant should remain in hospital for at least 24 hours and observations of temperature, pulse and respiratory rate performed 3 hourly and recorded on a NEWS chart.

GBS prophylaxis is offered by maternity staff to the mother and this must be adequately explained. If the clinician is unable to answer any queries then a relevant professional should be asked to address any concerns. This should conclude with a decision as to whether prophylaxis is accepted or declined and this must be clearly documented.

When prophylaxis or empirical treatment is declined by informed parents, this should be documented. It is not appropriate to suggest or instigate child protection proceedings.

The baby should be monitored on a NEWS chart and treated with antibiotics if abnormal clinical signs or symptoms are identified (refer to EOS guideline for details). Parents may not decline therapy for their baby if signs or symptoms of infection are present.

Appendix 1 Teicoplanin Dose Banding for GBS Prophylaxis

  Most recent weight   Dose (mg)
  Less than 36 kg   400mg
  36 - 45.9 kg   500mg
  46 - 53.9 kg   600mg
  54 - 61.9 kg   700mg
  62 kg or above   800mg

Editorial Information

Last reviewed: 19/02/2019

Next review date: 23/05/2024

Author(s): Ann Duncan.

Approved By: Obstetrics Clinical Governance Group

Document Id: 570

References

RCOG. Prevention of early-onset neonatal group B streptococcal disease. [Green-top Guideline No 36] September 2017.

NICE. Antibiotics for early-onset neonatal infection. [CG149] August 2012.